Reviva Pharmaceuticals Holdings Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the quarterly period ended March 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from____to ____ Commission file number: 001-38634 Reviva Pharmaceuticals Holdings, Inc.(Exact name of registrant as specified in its charter) Delaware85-4306526(State or other jurisdiction of(I.R.S. Employer Identification No.)incorporation or organization) 10080 N. Wolfe Road, Suite SW3-200Cupertino, CA95014(Address of principal executive offices)(Zip Code) (408) 501-8881(Registrant’s telephone number, including area code) Not applicable(Former name, former address and former fiscal year,if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, par value $0.0001 per shareRVPHThe Nasdaq Capital Market* *Trading of the registrant’s common stock on Nasdaq will be suspended on May 14, 2026. The registrant’s common stock will bequoted on the OTCQB Venture Market operated by OTC Markets Group Inc. under the symbol “RVPH”. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐ Accelerated filer☐ Non-accelerated filer☒ Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ As of May 13, 2026 the number of outstanding shares of the registrant’s common stock, par value $0.0001 per share, was13,110,377. REVIVA PHARMACEUTICALS HOLDINGS, INC.FORM 10-Q TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1. Financial Statements REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) March 31,December 31,20262025AssetsCash and cash equivalents$22,190,231$14,438,792Prepaid clinical trial costs819,721—Prepaid expenses and other current assets549,684664,685Total current assets23,559,63615,103,477Non-current prepaid clinical trial costs—819,721Total Assets$23,559,636$15,923,198 REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) REVIVA PHARMACEUTICALS HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 1.ORGANIZATION AND NATURE OF OPERATIONS On December 14, 2020, our predecessor company, formerly known as Tenzing Acquisition Corp., a British Virgin Islandsexempted company (“Tenzing”), and Reviva Pharmaceuticals, Inc., a Delaware corporation (together with its consolidatedsubsidiaries, “Old Reviva”), consummated the transactions (the “Business Combination”) contemplated by the Agreement and Planof Merger, dated as of July 20, 2020 (as amended, the “Merger Agreement”), by and among Tenzing, Tenzing Merger SubsidiaryInc., a Delaware corporation and wholly-owned subsidiary of Tenzing (“Merger Sub”), Old Reviva, and the other parties thereto.Pursuant to the Merger Agreement, Merger Sub merged with and into Old Reviva, with Old Reviva surviving as our wholly ownedsubsidiary. We refer to this transaction as the Business Combination. In connection with and one day prior to the completion of theBusiness Combination, Tenzing re-domiciled out of the British Virgin Islands and continued as a company incorporated in the Stateof Delaware and changed its name to Reviva Pharmaceuticals Holdings, Inc. (together with its consolidated subsidiaries, the“Company”). Prior to the completion of the Business Combination, the Company was a shell company. Following the BusinessCombination, the business of Old Reviva is the b